The most common, persistent concern among survivors of breast cancer is the fear that their disease will return, yet to the authors' knowledge, few interventions targeting fear of cancer recurrence (FCR) have been developed to date. The current pilot study examined the feasibility, acceptability, and preliminary efficacy of a home-delivered cognitive bias modification intervention to reduce FCR. The intervention, called Attention and Interpretation Modification for Fear of Breast Cancer Recurrence (AIM-FBCR), targeted 2 types of cognitive biases (ie, attention and interpretation biases). METHODS: A total of 110 survivors of breast cancer were randomized to receive 8 sessions of 1 of 2 versions of AIM-FBCR or a control condition program. Computer-based assessments of cognitive biases and a self-report measure of FCR were administered before the intervention, after the intervention, and 3 months after the intervention. RESULTS: Improvements in health worries (P 5.019) and interpretation biases (rates of threat endorsement [P<.001] and reaction times for threat rejection [P 5.007]) were found in those survivors who received AIM-FBCR compared with the control arm. Although only 26% of participants who screened into the study agreed to participate, the trial otherwise appeared feasible and acceptable, with 83% of those who initiated the intervention completing at least 5 of 8 sessions, and 90% reporting satisfaction with the computer-based program used. CONCLUSIONS: The results of the current pilot study suggest the promise of AIM-FBCR in reducing FCR in survivors of breast cancer. Future research should attempt to replicate these findings in a larger-scale trial using a more sophisticated, user-friendly program and additional measures of improvement in more diverse samples. Cancer 2017;123:1424-33. V C 2017 American Cancer Society.
INTRODUCTION
The most common, persistent concern among breast cancer survivors (BCS) is fear of cancer recurrence (FCR), 1 with rates ranging from 47% to as high as 99%. [2] [3] [4] [5] Although some FCR is normative, maladaptive levels of fear can be impairing. 3, 4, 6, 7 Increased FCR in BCS is associated with a decreased quality of life and increased distress, depression, and maladaptive behaviors, including increased body monitoring, medical visit anxiety, and preoccupation with health. 3, 4, 6 Despite this, to the best of our knowledge, to date, few psychosocial interventions have been designed to target FCR. [8] [9] [10] In fact, BCS report that their greatest unmet need is the management of FCR. 11 Cognitive models of anxiety posit that cognitive biases, such as selective attention to threat-relevant stimuli (attention bias) 12 and interpreting ambiguity in a threatening manner (interpretation bias), 13 play a key role in the etiology and maintenance of maladaptive levels of anxiety. Studies focusing on cancer suggest that cognitive biases may contribute to FCR in survivors and that such biases may be an important target for intervention. [14] [15] [16] [17] A substantial literature has shown that cognitive biases can be altered through brief, computerized interventions referred to as cognitive bias modification (CBM), which involve the rapid presentation of stimuli (eg, 500 milliseconds [ms] ) and repeated practice (eg, 360 trials) on cognitive tasks designed to encourage shifts in attention or interpretation. [18] [19] [20] CBM has demonstrated efficacy in improving a variety of conditions, including social anxiety, panic, and generalized anxiety disorders.
We developed a CBM intervention to target FCR in BCS, adapting a program originally developed for anxiety disorders. 21 This intervention, Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence (AIM-FBCR), attempts to maximize efficacy by targeting both attention and interpretation biases 22 ; personalizing it with an individual's greatest worries, 23 including a version of AIM-FCBR that used meaningful stimuli, which may have additional psychological benefits 24, 25 ; and allowing for completion of the treatment at home. The purpose of the current pilot study was to examine the feasibility, acceptability, and preliminary efficacy of AIM-FBCR. We hypothesized that AIM-FBCR would be feasible and would reduce FCR compared with a control condition (CC).
MATERIALS AND METHODS

Participants and Procedures
From October 2012 through November 2015, this parallel group randomized trial recruited a convenience sample of BCS diagnosed with stage 0 to stage III breast cancer (American Joint Committee on Cancer (AJCC) TNM staging system) who had no history of disease recurrence or metastases and who completed active treatment 3 months prior (could be receiving hormonal therapy), were aged > 18 years, were female, spoke English, and scored 3 on the Concerns About Recurrence Scale (CARS) Overall Fear Index, representing at least a low to moderate level of fear (53% of women screened). 26 Due to concerns about treatment-related cognitive side effects, we initially changed the eligibility criterion from 3 months after treatment to 1 year after treatment but subsequently changed the criterion back to 3 months because experts in neurocognitive functioning among BCS indicated that CBM performance would not be adversely affected by any residual side effects that may be present. In accordance with an assurance filed with and approved by the US Department of Health and Human Services, after Institutional Review Board approval, potential participants were invited to participate through letters, clinic approaches, and advertisements. Informed consent was obtained for each participant. Sample size was determined by resource constraints for this pilot trial, with the expectation of reaching 80% statistical power if the between-group effect sizes for the primary psychological outcomes of interest (CARS subscales scores) were 0.81.
This study has a ClinicalTrials.gov identifier (NCT01517945).
With a goal of enrolling 25 completers per arm for this pilot study, accounting for an attrition rate of approximately 30%, 110 participants were randomized (1:1:1) to receive 1 of 2 versions of AIM-FBCR (38 for the neutral version of AIM [AIM-Neutral] and 36 for the meaning version of AIM [AIM-Meaning]) or a CC program (36 participants). A total of 97 participants provided data for the pre-intervention (T1) period, (12% attrition rate), and 78 completed the intervention and provided data for the post-intervention (T2) period (20% attrition rate from T1). Of these 78 participants, 75 provided data for the 3 months post-intervention (T3) period (23% attrition rate from T1) (Fig. 1 ). Participants were blinded to assignment. The allocation sequence was generated by an institutional program that uses randomly permuted blocks. Randomization was stratified by disease stage (stages 0-I vs stages II-III disease). Cognitive bias and psychosocial outcomes assessments were administered preintervention (T1), post-intervention (T2), and at 3 months post-intervention (T3).
Cognitive Bias Assessments
Stimuli
The stimulus pool for the assessments and interventions was developed by compiling stimuli from previous studies of cognitive biases [16] [17] [18] and piloting them with 10 women endorsing FCR (CARS 3). The study team removed the least emotionally charged stimuli, yielding a final set of 83 neutral-threat word pairs, 107 meaning-threat word pairs, and 78 threat-neutral word/ambiguous sentence pairs, all matched for length and frequency of use.
Bias assessments
Attention bias was assessed via a modified dot-probe task. 27 In this task, individuals with an attention bias toward threat information theoretically should respond more quickly (lower reaction time, fewer ms) to congruent trials (in which a probe replaces a threatening stimulus) because their attention will be captured by the threatening stimulus. In contrast, reaction times should be slower for incongruent trials (in which the probe shows up in the opposite location of the threatening stimulus) because they will have to disengage their attention from the location of the threatening stimulus to identify the probe (more ms). The task used in the current study had 144 trials comprised of combinations of 2 (probe type: the letters E/F) by 2 (probe position: top/bottom) by 2 (neutral word position: top/bottom) by 9 (words) by 2 repetitions. After presentation of a fixation cue, the computer presented neutral-threat word pairs (eg, "sculpturemalignant") for 500 ms followed by a probe (the letter E or F) in the previous location of one of the words.
Participants were instructed to indicate whether the letter was an E or an F with a click of the corresponding button on the mouse. Attention bias "bottom bias" scores were calculated according to recent guidelines 28 by subtracting reaction times for theoretically fast trial types (probe congruent with threat word) from slow trial types (probe incongruent with threat word), using trials in which the probe appeared in the bottom location.
Interpretation bias was assessed via a word-sentence association paradigm (WSAP) 29 with 118 trials of wordsentence pairings measuring endorsement rates and reaction times for threat and benign interpretations of ambiguous sentences. At the beginning of the study, participants completed 144 trials. In August 2013, 13 ambiguous situations were removed from the assessment stimuli to improve the intervention. Each WSAP trial began with a fixation cross for 500 ms, followed by a word representing either the threat or benign interpretation of an ambiguous sentence appearing on the screen for 500 ms, followed by the ambiguous sentence (eg, "suspicious mass" or "thorough" appeared before the sentence, "The technician takes additional scans."). Participants were asked to indicate whether the word and sentence were related by pressing keyboard keys. We calculated the percentage of threat (ie, "rate of threat endorsement") and benign interpretations (ie, "rate of benign endorsement") endorsed and the mean reaction time to make each response (eg, "reaction time for threat rejection").
Treatment Conditions
AIM-FBCR intervention
AIM-FBCR consisted of 8 personalized treatment sessions of 30 minutes each administered twice a week for 4 weeks, as was done in prior studies. [19] [20] [21] 27, 30 Session 1 was completed in the clinic, whereas sessions 2 to 8 were completed at home. Sessions involved the completion of an attention modification task (CBM-A) followed by an interpretation modification task (CBM-I). Two versions of Denominator is total approached. c Denominator is total declined to participate. Denominator is total passive refusal.
e Denominator is total randomized.
AIM-FCBR were developed. AIM-Neutral modeled prior studies that paired neutral and threatening words in CBM-A. 27 AIM-Meaning was developed to determine whether there was any added value in redirecting attention toward a positive stimulus in CBM-A because research, including our own, has suggested that increasing a sense of meaning in life plays a protective role in adjustment among patients with cancer. 24, 25, 31 We thus piloted a version of AIM-FBCR that was slightly modified, redirecting attention away from threat and toward positive and meaningful stimuli.
CBM-A consisted of 160 trials of a modified dotprobe task 27 involving either neutral-threat pairs (eg, "sculpture-malignant") in AIM-Neutral or meaningthreat pairs (eg, "grandchild-malignancy") in AIMMeaning. CBM-A was identical to the attention bias assessment, except that to direct attention away from threat, the probes always replaced the neutral words (eg, "magazine") for AIM-Neutral or meaning words (eg, "grandchild") for AIM-Meaning. CBM-I consisted of 100 trials (4 participants underwent 96 or 98 trials due to a system error) of a modified WSAP 30 that were identical to the interpretation bias assessment, except that participants received feedback regarding their responses. The program provided positive feedback ("You are correct!") when participants endorsed benign interpretations or rejected threat interpretations. Negative feedback ("You are incorrect.") was provided when participants endorsed threat interpretations or rejected benign interpretations. The 2 versions of AIM-FBCR were identical for CBM-I (see Supporting Information Fig. 1 ).
Control condition
The CC followed procedures identical to those for AIM-FBCR; however, in the CBM-A task, trials included 10 neutral-threat pairs and 10 meaning-threat pairs, and the probe replaced neutral/meaning and threat words with equal frequencies. In the CBM-I task, participants were reinforced 50% of the time for making either benign or threat interpretations.
Personalization and ideographic selection
Participants rated a pool of words and sentences on a scale of -3 to 1 3 for how threatening or meaningful they were to them personally before their first session. Study staff selected the 20 words rated as most threatening (if receiving AIM-Neutral or CC) or 20 pairs of the most threatening and meaningful words (if receiving AIM-Meaning) to personalize CBM-A. Staff selected the 50 most threatening ambiguous sentences to personalize CBM-I.
Additional Measures
Demographic, medical, and mental health information was assessed at T1, with physical and mental health status updates obtained at T2 and T3.
Feasibility and acceptability
We assessed feasibility by measuring the percentages of patients who agreed to be screened, consented, declined participation, or dropped out. Reasons for refusal were assessed. Completers were defined as those completing at least 5 of the 8 sessions. Acceptability was evaluated during a post-treatment qualitative exit interview in which participants were asked how satisfied they were with the program overall. Our acceptability target was mostly feedback indicating satisfaction and minimal dissatisfaction.
Primary Outcome (Efficacy of AIM-FBCR Versus CC)
The primary FCR outcome was the CARS, 26 a widely used, reliable, 30-item self-report measure that assesses the extent and nature of a woman's FCR. Subscales include: Overall Fear (4 items regarding the frequency/intensity of FCR), Health Worries (11 items regarding potential medical treatment or declines in physical health), Womanhood Worries (7 items regarding womanhood, sexuality, romantic relationships, and identity), Role Worries (6 items regarding responsibilities at work, at home, and with friends and family), and Death Worries (2 items regarding the possibility of death). 26 Items were rated on a scale of 1 (no fear) to 6 (intense/frequent fear) for Overall Fear, and from 0 ("Not at all") to 4 ("Extremely") on all other scales. Mean scores were calculated for each subscale.
Statistical Analysis
Descriptive statistics were computed to characterize feasibility and acceptability. Differences between subsets of participants (eg, between treatment conditions) were evaluated using Pearson chi-square tests, Fisher exact tests, and Student t tests. To evaluate preliminary efficacy, repeated outcomes (eg, T1, T2, and T3 CARS scores) were entered into generalized estimating equation 32 models, clustering by participant and including a time main effect (dummy-coded for T2 and T3, with T1 as the reference group), a randomization assignment main effect, and a time by randomization interaction effect. Statistical significance of model terms was evaluated using the Wald's chi-square statistic. Covariates also were included. Standardized Hedges g 33 was used as a measure of effect size. Data were analyzed according to the intention-to-treat principle. To evaluate the impact of missing data, analyses were run again with data sets created using multilevel multiple imputation (MI) conducted with the SAS MMI_IMPUTE macro (SAS Institute Inc, Cary, NC). 34, 35 Data were imputed at the item level. Results from imputation models were pooled to derive parameter estimates. A reliable change index (RCI) was calculated for FCR. 36, 37 The percentages of participants demonstrating reliable changes in the AIM-FBCR and CC arms were compared using a Pearson chi-square test; in calculating an individual's RCI, 2-month test-retest reliability from a study using a Dutch version of the CARS was used as an estimate of each subscale's reliability. 34 Associations between changes in cognitive biases and changes in FCR were examined using the Pearson correlation coefficient.
Post-treatment exit interviews were audiotaped, transcribed, coded, and analyzed by 2 blinded, independent coders (E.S. and K.R.) using thematic content analysis 38 and established techniques 39 to achieve consensus regarding responses related to program satisfaction. Analyses were performed using IBM SPSS statistical software (version 21; IBM Corporation, Armonk, NY) and SAS statistical software (version 9.4; SAS Institute Inc). Table 1 shows participant characteristics. Compared with AIM-FBCR participants, CC participants were significantly further out from treatment (P 5 .036) and had significantly different hormonal treatment histories (P 5 .028). . Approximately 12% of those enrolled dropped out of the study after providing informed consent, and 10% dropped out after their first session. Figure  1 shows reasons for declining. There were no significant demographic differences noted between completers and noncompleters. However, completers scored significantly lower on the CARS Role Worries subscale (P 5 .019) at T1. Thematic analysis of the available exit interviews (77 participants) revealed that 90% (69 of 77 participants) reported being at least somewhat satisfied with the computer program. Despite this general satisfaction, 52% (40 of 77 participants) suggested a more userfriendly, visually appealing interface such as a mobile phone application.
RESULTS
Participant Characteristics
Efficacy
Patterns of findings in the 2 versions of AIM-FBCR were similar (P values > .10); thus, we collapsed across versions. See Supporting Information Tables 1 and 2 for results by treatment arm. Controlling for age, stage of disease, time since treatment, educational level, and hormonal treatment history did not appear to impact the significance level of the findings below, and therefore unadjusted results are presented.
Fear of Cancer Recurrence
There was a significant Time AIM-FBCR participants exhibited reductions in the other CARS subscales as well, although these were not found to be significantly different from reductions for CC participants (P values>.10; between-group g range of 0.20-0.41 at T2 and 0.13-0.37 at T3).
Cognitive biases
For the dot-probe task, inaccurate trials were excluded, and reaction times for both bias assessments were winsorized. 28 There was no significant effect of Time 3 Condition with regard to attention bias. However, there were significant effects of Time g 5 0.93; P 5 .002). Improvements were similar at the T3 assessment (P values<.05). It also is interesting to note that improvements in Reaction Time for Threat Rejection at T2 were found to be significantly correlated with improvements in CARS Health Worries (r(73), 0.24; P 5 .042). When analyses were conducted with MI, improvements in Rate of Threat Endorsement for AIM-FBCR participants compared with CC participants remained significant at T2 and T3, and improvements in Reaction Time for Threat Rejection were still marginally significant at T2 and no longer were significant at T3.
DISCUSSION
The current study evaluated the feasibility, acceptability, and preliminary efficacy of an intervention targeting cognitive biases associated with FCR. In a sample of BCS with at least moderate levels of FCR, AIM-FBCR was found to significantly reduce health worries. Levels of worry in women who received the intervention decreased from high-moderate to less than moderate 3 months after the intervention, whereas worry levels in women in the CC group remained relatively stable (Fig.  1) . Although quantitatively small, this improvement is potentially clinically meaningful, especially given the minimal time and financial cost of AIM-FBCR. In addition, the rate of reliable improvement among AIM-FBCR participants was approximately 2 times the rate among CC participants. The current study finding that Health Worries was the only CARS subscale that improved is likely due to the stimuli used to populate the AIM-FBCR intervention, which were threatening health-related and treatmentrelated words and sentences. There also may have been placebo improvement in the CC arm; this appears particularly likely for the Overall Fear subscale, on which the CC group demonstrated substantially more improvement over time compared with the other subscales. This may be due to its use as a screening measure, which primed responses indicating benefit. Similar patterns were observed in a recent study testing a gratitude intervention, which resulted in improvements in only one of the CARS subscales, Death Worries, 10 and not the Overall Fear subscale, suggesting that a strength of the CARS is its ability to truly tap into different aspects of multidimensional FCR.
The hypothesized mechanism of change in CBM interventions is a reduction in cognitive biases. Indeed, AIM-FBCR participants demonstrated decreased rates of negative interpretations compared with CC participants. However, consistent with previous CBM trials, 40, 41 no significant group differences emerged on the attention bias assessment. Thus, it is possible that observed changes in FCR are due mostly to changes in interpretation biases. Alternatively, it is possible that the program did affect attention, but the dot-probe task, which some consider unreliable, 42 was not sensitive to this. Although not as large in magnitude, CC participants also experienced improvements. In addition to general placebo effects, improvements in the CC group may be due to essentially receiving a "diluted" treatment. In effect, they received feedback that they were correct in accepting a benign/rejecting a threatening interpretation in CBM-I or when they were redirected away from threatening stimuli in CBM-A, both of which happened approximately 50% of the time with the CC intervention. Finally, there may be effects resulting from exposure to anxiety-provoking stimuli.
Although some metrics of feasibility were strong, such as the majority of participants who initiated the intervention completing it, only approximately 26% of women who screened in with the CARS agreed to participate. Feasibility was found to be negatively affected by the need to complete one session in the office and the reliance on Windows (Microsoft Corporation, Redmond, Wash)-based computers. One of the most common participant complaints was technical difficulties with the AIM-FBCR computer program. This was a recognized limitation of the current pilot study, and future studies should refine the technology. Nonetheless, the findings herein suggest the potential of a CBM approach in reducing FCR, either alone or as a complement to psychotherapy. 43 The results of the current study suggest the promise of AIM-FBCR as a low-cost, easily disseminated, homedelivered intervention with the potential to reduce FCR. Strengths of the study include the randomized controlled and mixed methods design. Limitations include a small, homogenous sample; potential selection bias due to study refusal, with only approximately 25% of women who screened into the study enrolling, and attrition; and reliance on a self-report measure of FCR. In addition, differences among participants who dropped out may have played a role in some of the observed results. However, it is important to note that improvement in the Health Worries subscale was robust at follow-up, accounting for missing data.
Future research should attempt to replicate these findings in a larger-scale randomized controlled trial using a more sophisticated, user-friendly computer program that can be used on portable devices in diverse samples.
It also may be valuable to test a more diverse pool of recurrence-related stimuli to target other domains of FCR. Trials should include clinician-rated and neurobiological measures of improvement (eg, electroencephalography) 44 and may screen for cognitive biases at baseline. Treatment response moderators and dose modifications also should be examined. Finally, given that FCR is one of the greatest concerns for survivors of a variety of cancers, 45 if it proves efficacious, this approach also could be adapted for other survivor populations.
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